NEW YORK, June 20 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), announced today it has retained Strategic Growth International, Inc. ("SGI"), a global investor relations firm, to assist the Company in growing its financial market presence. SGI will assist the Company in establishing a stronger understanding of the investment opportunity AMDL represents while increasing the Company's awareness across global investment communities.
Gary Dreher, CEO of AMDL, commented, "As we continue building AMDL into a world-class pharmaceutical company we feel strong communications is imperative to our success. SGI has a strong reputation with an exceptional team and we're excited to have them as a partner to communicate our corporate story, the great progress we're making with new products and technologies in the U.S., China, and other global markets, and most important, how we intend to meet our stated financial targets of doubling annual sales consecutively over the next 3 years."
SGI Co-Founder Rich Cooper also commented saying, "We believe a strong investment story exists with AMDL and we're excited the company has chosen us to support their IR efforts. Through our combined efforts we will focus on achieving a fair and sustainable market valuation for AMDL while enhancing their reputation with investors, analysts, and the financial media."
Founded in 1989, SGI is headed by Richard E. Cooper and Stanley Altschuler, both long-time and highly-respected Wall Street veterans. Prior to his co-founding SGI, Mr. Cooper was a Managing Director at Salomon Brothers for five of his 14 years at the firm. Mr. Altschuler owned and managed a New York-based brokerage firm.
AMDL, Inc. is a global specialty pharmaceutical company. The Company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com.
The Private Securities Litigation Reform Act of 1995 provides a safe
harbor for forward-looking statements made by the Company or on its behalf.
This news release contains forward-looking statements, which are subject to
certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our ability to
successfully complete Phase III clinical trials and secure regulatory
approval of our current or future drug-delivery system and uncertainties
regarding our ability to obtain financial and other resources for any
research, development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the
date they are made.
AMDL Contact: Investor Relations Contact:
Kristine Szarkowitz Strategic Growth International, Inc.
Director-Investor Relations Richard E. Cooper - email@example.com
firstname.lastname@example.org Cass Almendral - email@example.com
(206) 310-5323 (212) 838-1444/ http://www.sgi-ir.com
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved